<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30408551</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-0038</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Gene</Title>                <ISOAbbreviation>Gene</ISOAbbreviation>            </Journal>            <ArticleTitle>EZH2-mediated epigenetic suppression of EphB3 inhibits gastric cancer proliferation and metastasis by affecting E-cadherin and vimentin expression.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S0378-1119(18)31158-2</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2018.11.015</ELocationID>            <Abstract>                <AbstractText>EphB3 is a member of the EPH family of receptors and has been found to play a role in the carcinogenesis of some human cancers. However, its expression and clinical significance in gastric cancer (GC) have not been well documented. In the present study, we detected the expression of EphB3 in GC and adjacent noncancerous tissues and explored its relationships with the clinicopathological features and prognosis of GC patients. It was found that EphB3 silenced GC cells epigenetically by direct transcriptional repression of GC cells via polycomb group protein EZH2 mediation. EphB3 was downregulated in GC cells and tissues, and EphB3 depletion promoted GC cell growth and invasion, while ectopic overexpression of EphB3 produced a significant anti-tumor effect. EphB3 was found to be involved in epithelial-mesenchymal transition by regulating E-cadherin and vimentin expression. In addition, patients with reduced EphB3 expression had shorter disease-free survival (DFS), indicating that EphB3 may prove to be a biomarker for prognosis of GC. These results demonstrated that EphB3 functioned as a tumor-suppressor and prognostic biomarker in GC.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier B.V.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Kun</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>He</LastName>                    <ForeName>Jing</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yan-Fen</ForeName>                    <Initials>YF</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, The First People's Hospital of Yangzhou/The Second Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jin</LastName>                    <ForeName>Shi-Dai</ForeName>                    <Initials>SD</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fan</LastName>                    <ForeName>Yu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Institute, the Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fang</LastName>                    <ForeName>Na</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Institute, the Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qian</LastName>                    <ForeName>Jun</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou Cancer Medical Center, Suzhou, Jiangsu 215001, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Tong-Peng</ForeName>                    <Initials>TP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, People's Republic of China. Electronic address: tongpeng_xu_njmu@163.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guo</LastName>                    <ForeName>Ren-Hua</ForeName>                    <Initials>RH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, People's Republic of China. Electronic address: rhguo@njmu.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Gene</MedlineTA>            <NlmUniqueID>7706761</NlmUniqueID>            <ISSNLinking>0378-1119</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">EZH2</Keyword>            <Keyword MajorTopicYN="N">EphB3</Keyword>            <Keyword MajorTopicYN="N">Epithelial–mesenchymal transition</Keyword>            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>            <Keyword MajorTopicYN="N">Proliferation and metastasis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>11</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30408551</ArticleId>            <ArticleId IdType="pii">S0378-1119(18)31158-2</ArticleId>            <ArticleId IdType="doi">10.1016/j.gene.2018.11.015</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>